Navigation Links
Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
Date:5/14/2008

elcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in a Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements regarding the further development and potential safety, efficacy, regulatory status, commercial potential and other characteristics of Kosan's product candidates; the continuation of current clinical trials; the initiation of additional clinical trials and the timing thereof and the use of Kosan's financial resources. Words such as "will," "expect," "believe," "may," "intend," "plan," "potential" and similar expressions are intended to identify forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Kosan's current expectations. Forward-looking statements involve risks and uncertainties. Kosan's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the uncertain progress and r
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
7. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
8. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
9. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... and VANCOUVER , July 2, 2015 /PRNewswire/ ... announced today that its common shares have been approved for ... the symbol "EPIX". ESSA will begin trading on ... listing on the TSX Venture Exchange under the symbol "EPI". ... common shares on the NASDAQ, each of the Company,s outstanding ...
(Date:7/2/2015)... -- Before you head outdoors with your family to enjoy the ... healthy. Take steps to protect yourself from the sun, bugs ... Protect Your Skin From the Sun Exposure to ... of skin cancer. To protect your skin from UV radiation, ... midday hours. Wear a hat with a wide brim to ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/n7kzjb/vitamin_d_market ) has announced the ... End-User & by Region - Global Trends & Forecast to ... is projected to reach about $2.5 Million by 2020, with ... opportunities in countries such as India , ... and Brazil . In 2013, the North ...
Breaking Medicine Technology:ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4First Aid Summer Survival Tips from Nyack Hospital 2First Aid Summer Survival Tips from Nyack Hospital 3Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 2Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 3
... 25, 2011 Wolters Kluwer Pharma Solutions, Inc., a ... healthcare professionals, today announced that Rep. Ben Quayle ... this week with its healthcare analytics management team to discuss ... America.  Congressman Quayle visited the company,s offices on Camelback Road ...
... 2011 Innovation, makers of PharmASSIST® pharmacy automation solutions, ... today announced that they have signed a partnership agreement ... of automated, high density robotic storage and retrieval systems ... (#782) at the upcoming NACDS Pharmacy & Technology Conference ...
Cached Medicine Technology:Congressman Quayle Talks With Wolters Kluwer Pharma Solutions About Importance of Health Information 2Congressman Quayle Talks With Wolters Kluwer Pharma Solutions About Importance of Health Information 3Innovation and RxSafe, LLC Partner to Bring Together Pharmacy Automation Product Suites 2
(Date:7/3/2015)... Lewisville, TX (PRWEB) , ... July 03, 2015 , ... ... said First Choice Emergency Room , the largest network of independent freestanding emergency ... the new facility medical director of our Sienna Plantation facility,” said Executive Medical Director ...
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and ... this week that he says will reveal biblical truth and expose popular lies regarding ... Your Bible Say Don’t Have Sex”, immediately goes into the core of the subject ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... sweetFrog Enterprises, ... Mississippi. The opening is the first sweetFrog store located in Mississippi. The premium frozen ... companies in 2014. , The store, located at 104 Railroad Avenue, New Albany, MS ...
(Date:7/2/2015)... ... July 02, 2015 , ... Following the recent report by ... obese Americans outnumber merely overweight Americans, Samir Becic emphatically declared a war on obesity ... society right now," Becic said. "We must understand the magnitude of this discovery. For ...
(Date:7/2/2015)... ... , ... Many Fourth of July celebrations will include fireworks this summer, so ... sharing some tips to promote the proper use of fireworks. , According to the ... daily with fireworks-related injuries in the month surrounding the Fourth of July. Amica is ...
Breaking Medicine News(10 mins):Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetfrog Opens First Location in Mississippi 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:6 Fireworks Safety Tips from Amica Insurance 2
... (Nice) said that doctors should not prescribe beta blockers ... watchdog’s said that drugs that are currently prescribed are ... the recent study it was found that beta-blockers though ... less serious side effects. ,Other treatments should ...
... now becomes more effective and safe with a newer, ... ,Tissue engineers and chemists at the University ... from simple polymers, which serve as an effective method ... ,This ultra-fine, 3-dimensional scaffold, which is made from ...
... accurately shown by an increased nighttime BP than with a ... the researchers at Uppsala University revealed that a high blood ... congestive heart failure. ,Congestive heart failure (CHF) ... diseases. Once diagnosed as having CHF, patients have a 1 ...
... found that Alzheimer’s damaged communication pathways between frontal and ... as long-term memory power. ,According to a ... Alzheimer’s disease plus recent memory loss may be linked ... ,For the first time, researchers at Duke University Medical ...
... today insisted that he and his colleague the Minister ... the Progressive Democrats Party and in Government. ... that relationship between the two Cabinet members McDowell tried ... the junior coalition partner. It was also suggested by ...
... has compiled a report on that details the top 10 ... 19 other scientists in the United States, Canada and Italy. ... on the reasons for obesity besides exercise and diet. They ... ,* Inadequate sleep: Sleep deprivation leads to some sort ...
Cached Medicine News:Health News:Fine Polymer Scaffolding – a Boon for Skin Reconstructio 2Health News:Increased Nighttime BP, a Significant Predictor of Congestive Heart Failure 2Health News:Memory Loss and Amnestic MCI – Precursors of Alzheimer Diseas 2
... CS and Alliance Catheter Delivery ... the introduction of catheters or ... from a superior approach. These ... outstanding peel-away introducer performance with ...
The AXIUS™ Blower/Mister provides controlled delivery of CO2 and saline to improve visibility during anastomosis....
... DYNALINK .018 Biliary Self-Expanding Stent System combines low-profile, ... system. This .018" guide wire compatible stent system ... in all diameters (5.0 - 10.0 mm). Now, ... is offered in five stent lengths (28, 38, ...
... comprise the world's broadest line of ... Their advanced catheter design and materials ... with a soft, atraumatic tip. Available ... Supreme and Response catheters provide outstanding ...
Medicine Products: